CCEL Form 4: 5,300-option grant vests monthly from Oct 2025

Rhea-AI Filing Summary

Cryo-Cell International (CCEL) filed a Form 4 reporting a director equity award. On 10/21/2025, director Daniel Mizrahi received a grant of stock options to purchase 5,300 shares at $4.35 per share, expiring on 10/21/2035. The options vest at a rate of 1/12 per month commencing on 10/21/2025.

Following the reported transactions, the reporting person directly beneficially owned 30,634 shares of common stock. The filing also lists prior option grants of 5,300 shares each dated 10/20/2021, 10/03/2022, 10/10/2023, and 10/29/2024 with exercise prices of $12.63, $6.50, $4.90, and $5.82, respectively.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mizrahi Daniel

(Last) (First) (Middle)

700 BROOKER CREEK BLVD.

SUITE 1800

(Street)

OLDSMAR FL 34677

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRYO CELL INTERNATIONAL INC [ CCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								30,634	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$12.63							10/20/2021	10/20/2031	Common Stock	5,300		5,300	D
Stock Option	$6.5							10/03/2022	10/03/2032	Common Stock	5,300		5,300	D
Stock Option	$4.9							10/10/2023	10/10/2033	Common Stock	5,300		5,300	D
Stock Option	$5.82							10/29/2024	10/29/2034	Common Stock	5,300		5,300	D
Stock Option	$4.35	10/21/2025		A		5,300		10/21/2025(1)	10/21/2035	Common Stock	5,300	$4.35	5,300	D

Explanation of Responses:

1. Stock options vest at a rate of 1/12 per month commencing on October 21, 2025.

	/s/ Daniel Mizrahi	10/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CCEL disclose in this Form 4?

A director, Daniel Mizrahi, was granted 5,300 stock options at $4.35 on 10/21/2025, vesting 1/12 monthly from that date and expiring on 10/21/2035.

How many CCEL common shares are beneficially owned after the transaction?

The reporting person directly beneficially owned 30,634 common shares following the reported transactions.

What is the vesting schedule for the new options at CCEL?

The options vest at a rate of 1/12 per month commencing on 10/21/2025.

Who filed the CCEL Form 4 and what is their role?

It was filed by Daniel Mizrahi, who serves as a Director of Cryo-Cell International.

What are the terms of prior CCEL option grants listed?

Prior grants are 5,300 options each dated 10/20/2021 at $12.63, 10/03/2022 at $6.50, 10/10/2023 at $4.90, and 10/29/2024 at $5.82.

What is the expiration date of the newly granted CCEL options?

The newly granted options expire on 10/21/2035.